ENA21 Poster 103

Introduction of a Single Strain of Bacillus into a Germ-Free Environment did not Impact the Anti-PD-1 Efficacy in a MC38 Syngeneic Model

Tao Yang¹, Bonnie Xiaobo Chen¹, Rongfei Lu¹, Annie X. An¹, Mingfa Zang¹, Jingjun Li¹, Sheng Guo¹, Wubin Qian¹, Jian Fei², Tongyang Hao³, Chen Xu⁴, Henry Q. X. Li^1
1Crown Bioscience Inc., 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, USA; ²Shanghai Model Organisms Center, Inc., 3577 Jinke Rd, Shanghai, 201203; ³GemPharmatech Co., Ltd, 12 Xuefu Rd, Jiangbei New Area District, Nanjing, 210061; ⁴Cyagen Biosciences Co. Ltd., Building 3, Biomedical Pioneer Park, Zhenhui Rd, Taicang, Suzhou, 215400LTS

Although immunotherapy has led to exceptional and durable clinical responses, the majority of patients respond poorly to the current immunotherapies. Growing evidence has linked some of the poor responsiveness to gut microbiota, and modulation of the gut microbiome composition is becoming a promising new strategy to enhance immune checkpoint inhibitor (ICI) treatment outcome.

In our poster, discover how mouse tumor modelling under germ-free (GF) conditions combined with introduction of defined bacterial strains could be a useful approach to investigate the impact of microbiota on ICI efficacy, as well as understanding the underlying mechanisms.

Download this Poster to Discover:

• How MC38 tumors exhibited slower growth but more robust response to anti-PD-1 monoclonal antibody (mAb) therapy in SPF mice in comparison with GF mice
  
  
• That GF mice and SPF mice displayed distinct immuno-profiles of TILs, e.g., higher frequency of TILs in SPF mice than in GF mice
  
  
• How the introduction of Bacillus into GF mice showed little impact on the efficacy of anti-PD-1 mAb therapy

Download the Poster Now!